SANOFI ADR

NASDAQ: SNY (Sanofi)

Last update: 26 Jul, 8:38PM

52.40

-0.70 (-1.32%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Sanofi Bullish Mixed

Stockmoo Score

0.8

Similar Stocks

Stock Market Cap DY P/E P/B
SNY 131 B 7.78% 28.79 1.94
AZN 272 B 1.70% 42.53 6.52
AMGN 172 B 2.77% 55.27 29.05
GILD 94 B 4.07% 91.62 5.38
GRFS 6 B - 29.50 0.980
BIIB 29 B - 25.45 1.85

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Core

Ownership

Name Date Shares Held
Mondrian Investment Partners Ltd 31 Mar 2024 3,951,089
52 Weeks Range
42.63 (-18%) — 55.72 (6%)
Median 60.00 (14.50%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Argus Research 26 Jul 2024 60.00 (14.50%) Buy 52.40

No data within this time range.

Date Type Details
02 Sep 2024 Announcement Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
02 Sep 2024 Announcement Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
09 Aug 2024 Announcement Sanofi: Information concerning the total number of voting rights and shares - July 2024
08 Aug 2024 Announcement Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
08 Aug 2024 Announcement Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
25 Jul 2024 Announcement Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
25 Jul 2024 Announcement Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
25 Jul 2024 Announcement Press Release: Online availability of Sanofi’s half-year financial report for 2024
25 Jul 2024 Announcement Press Release: Online availability of Sanofi’s half-year financial report for 2024
22 Jul 2024 Announcement Sanofi: Information concerning the total number of voting rights and shares – June 2024
17 Jul 2024 Announcement Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
17 Jul 2024 Announcement Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A
10 Jul 2024 Announcement Sanofi ships U.S. influenza vaccines for the 2024/25 season
03 Jul 2024 Announcement Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
03 Jul 2024 Announcement Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
26 Jun 2024 Announcement Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
26 Jun 2024 Announcement Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
25 Jun 2024 Announcement Press Release: Availability of the Q2 2024 Aide-mémoire
21 Jun 2024 Announcement Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
21 Jun 2024 Announcement Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
21 Jun 2024 Announcement Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran
20 Jun 2024 Announcement Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
20 Jun 2024 Announcement Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
12 Jun 2024 Announcement Sanofi: Information concerning the total number of voting rights and shares – May 2024
11 Jun 2024 Announcement Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
Show more
TTM Dividend Yield 7.78%
5Y Average Dividend Yield 3.78%
Expected Next Dividend Payment Jun 2025
Ex Date Announcement Date Payment Date Details
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Cash
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Cash
30 May 2023 - 23 Jun 2023 1.9000852 Cash
26 May 2022 - 27 Jun 2022 0.2971788 Cash
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Cash
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Cash
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Cash
07 May 2019 - 31 May 2019 1.722322 Cash
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Cash
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Cash
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Cash
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Cash
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Cash
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Cash
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Cash
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 4.07 2 7.78
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria